Searched for
SUN RANBAXY MERGER
18 top Ranbaxy executives including Indrajit Banerjee, Yugal Sikri, get marching orders as part of integration plan with Sun PharmaThe executives have been given a severance package and the freedom to exercise their stock options before leaving.- Ranbaxy shares to stop trading on exchanges from April 6In April, 2014, Sun Pharma had announced it would acquire Ranbaxy in an all-stock transaction worth USD 4 billion that includes $800 millio...
- Shares of Sun Pharma, Ranbaxy rise after regulatory nods for merger dealAt end of trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 per cent and Ranbaxy Laboratories closed at Rs 819.55 apiece, ...
- Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
- Sun Pharma gets RBI nod for transfer of Ranbaxy's overseas investmentsThe central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...
- Sun Pharma-Ranbaxy merger may put pressure on Ebitda margins of merged entity: Daljeet Singh KohliHow Sun Pharma integrates its business will be keenly followed, says Kohli. Merged entity will take some time to derive synergistic benefit...
- Ranbaxy, Sun Pharma gain on merger nodRanbaxy Laboratories rose by 2.37% to settle at Rs 720.35 on the BSE. In intra-day trade, it jumped 3.46% to touch 52-week high of Rs 728.
- Ranbaxy Lab, Sun Pharma gain up to 3.5 per cent as CCI clears dealShares of Ranbaxy Lab & Sun Pharma gained up to 3.5% at close after CCI cleared their long-pending $4-billion merger, though with riders.
- Competition Commission of India may okay Sun-Ranbaxy deal with riderThe watchdog may have to set up a mechanism to ensure that the company complies with the steps it prescribed after completion of the merger.
- Andhra High Court order not to impact merger with Ranbaxy: Sun PharmaLast week, the court had vacated the status quo order it had issued earlier on the merger process between Sun Pharma and Ranbaxy.
- Andhra HC vacates status quo order on Sun Pharma-Ranbaxy mergerThe Andhra Pradesh high court on Saturday vacated stay orders it issued last month on the merger of two firms that would create world’s fou...
- Andhra Pradesh High Court verdict on Sun Pharma-Ranbaxy merger plea tomorrowAfter hearing the arguments from the counsels of the petitioners, Ranbaxy, Sun Pharma and SEBI, Justice G Chandraiah said he will pronounce...
- Andhra HC verdict on Sun Pharma-Ranbaxy merger plea tomorrowThe court had earlier issued interim orders to maintain status quo with regard to the merger.
- SC asks Andhra HC to decide on Ranbaxy-Sun Pharma mergerTwo individual investors alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6.
- Daiichi files plea in Andhra Pradesh HC to vacate stay on Sun-Ranbaxy mergerThe drug maker also said that the petitioners have intermingled two separate issues - insider trading and merger process of Sun Pharma and ...
- Talented Ranbaxy executives needn’t worry: Daiichi SankyoGeorge Nakayama asked ‘talented’ executives in Ranbaxy Labs to not unduly worry about their prospects in the backdrop of the company gettin...
- Ranbaxy-Sun Pharma merger deal may close by 2014 end: Daiichi SankyoThe $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.
- Buy Sun Pharma shares through RanbaxyAn investor who is really confident that the deal will go through can buy Ranbaxy shares and pocket the difference when the merger is compl...
- Merger with Sun Pharma will spell the end of Ranbaxy brand, but a new dawn beckonsSun Pharma may not have to face surprises emanating from Ranbaxy. There is every likelihood that brand Ranbaxy will see a sunset clause whe...
- Sun Pharma to buy Ranbaxy in $3.2 bn deal: HighlightsSun Pharmaceutical Industries said that it will buy generic drug maker Ranbaxy Laboratories, has hit regulatory snags in its key US market ...
Load More
